{"entity":{"id":"nct06441565","kind":"trial","name":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","aka":[],"tldr":"A phase 2/3 trial of fruquintinib, fluorouracil (5-FU) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT06441565 by Sun Yat-sen University, with a registry enrolment figure of 84 participants, started 2024-05-24 and due to reach its primary completion in 2025-12-30. Interventions recorded: Fruquintinib; Fluorouracil; Oxaliplatin. Conditions listed: Colorectal Cancer. Primary outcome: 6-month progression-free survival. Colorectal eligibility wording from the registry: \"* Histologically confirmed colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06441565","url":"https://clinicaltrials.gov/study/NCT06441565"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","kinase-inhibitors","platinum"],"targets":[],"drugs":["fruquintinib","fluorouracil","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06441565","phase":"2/3","setting":"Fruquintinib Plus Arterial Infusion Therapy With Hepatic FOLFOX for Refractory Colorectal Cancer: The FAITH Randomized Clinical Trial","sponsor":"Sun Yat-sen University","enrolled":84,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06441565/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}